- Home
- FRGE vs ACRV Comparison
FRGE vs ACRV Comparison
Compare FRGE & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRGE
- ACRV
- Stock Information
- Founded
- FRGE 2014
- ACRV 2018
- Country
- FRGE United States
- ACRV United States
- Employees
- FRGE N/A
- ACRV N/A
- Industry
- FRGE Computer Software: Prepackaged Software
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- FRGE Technology
- ACRV Health Care
- Exchange
- FRGE Nasdaq
- ACRV Nasdaq
- Market Cap
- FRGE 196.1M
- ACRV 203.9M
- IPO Year
- FRGE N/A
- ACRV 2022
- Fundamental
- Price
- FRGE $0.94
- ACRV $6.60
- Analyst Decision
- FRGE Strong Buy
- ACRV Strong Buy
- Analyst Count
- FRGE 3
- ACRV 5
- Target Price
- FRGE $4.50
- ACRV $22.40
- AVG Volume (30 Days)
- FRGE 710.3K
- ACRV 63.0K
- Earning Date
- FRGE 11-06-2024
- ACRV 11-13-2024
- Dividend Yield
- FRGE N/A
- ACRV N/A
- EPS Growth
- FRGE N/A
- ACRV N/A
- EPS
- FRGE N/A
- ACRV N/A
- Revenue
- FRGE $79,799,000.00
- ACRV N/A
- Revenue This Year
- FRGE $19.18
- ACRV N/A
- Revenue Next Year
- FRGE $34.32
- ACRV N/A
- P/E Ratio
- FRGE N/A
- ACRV N/A
- Revenue Growth
- FRGE 18.08
- ACRV N/A
- 52 Week Low
- FRGE $0.80
- ACRV $3.19
- 52 Week High
- FRGE $4.02
- ACRV $11.90
- Technical
- Relative Strength Index (RSI)
- FRGE 39.86
- ACRV 42.20
- Support Level
- FRGE $0.90
- ACRV $6.56
- Resistance Level
- FRGE $1.25
- ACRV $7.45
- Average True Range (ATR)
- FRGE 0.09
- ACRV 0.47
- MACD
- FRGE -0.01
- ACRV -0.00
- Stochastic Oscillator
- FRGE 2.14
- ACRV 28.12
About FRGE Forge Global Holdings Inc.
Forge Global Holdings Inc is a financial service platform created to serve the needs of the private market. It provides marketplace infrastructure, data services, and technology solutions for private market participants. The Company offers a trusted trading platform, proprietary data and insights to inform investment strategies, along with custody services to help companies, shareholders, institutions and accredited investors confidently navigate and transact in the private market.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.